1-Butyl-3-(2,4-difluorophenyl)-1-[1-[[4-[4-(methanesulfonamido)phenoxy]phenyl]methyl]piperidin-4-yl]urea

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-Butyl-3-(2,4-difluorophenyl)-1-[1-[[4-[4-(methanesulfonamido)phenoxy]phenyl]methyl]piperidin-4-yl]urea
• 化学式: C₃₀H₃₆F₂N₄O₄S
• 分子量: 586.7
• InChiKey: YCURGYXXQGJRET-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  41
• 可旋转键数：
  11
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  99.4
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient
  申请人：Nishizawa Rena

  公开号：US20060178399A1

  公开（公告）日：2006-08-10

  A compound represented by the following general formula (I), its salt, solvates thereof or prodrugs thereof: (wherein each symbol is as defined in the description.) The compounds represented by the general formula (I) are useful in preventing and/or treating various inflammatory diseases (asthma, nephritis, nephropathy, hepatitis, arthritis, rheumatoid arthritis, rhinitis, conjunctivitis, ulcerative colitis, etc.), immunological diseases (autoimmune diseases, rejection in organ transplantation, immunosuppression, psoriasis, multiple sclerosis, etc.), infection with human immunodeficiency virus (acquired immunodeficiency syndrome, etc.), allergic diseases (atopic dermatitis, urticaria, allergic bronchoplumonary aspergillosis, allergic eosinophilic gastroenteritis, etc.), ischemic reperfusion injury, acute respiratory distress syndrome, shock accompanying bacterial infection, diabetes, cancer metastasis and so on.

  以下是通式（I）所代表的化合物、其盐、溶剂化物或前药：（其中每个符号如描述中所定义）。通式（I）所代表的化合物在预防和/或治疗各种炎症性疾病（哮喘、肾炎、肾病、肝炎、关节炎、类风湿性关节炎、鼻炎、结膜炎、溃疡性结肠炎等）、免疫性疾病（自身免疫性疾病、器官移植排斥、免疫抑制、银屑病、多发性硬化症等）、人类免疫缺陷病毒感染（获得性免疫缺陷综合症等）、过敏性疾病（特应性皮炎、荨麻疹、过敏性支气管肺曲霉病、过敏性嗜酸性胃肠炎等）、缺血再灌注损伤、急性呼吸窘迫综合症、细菌感染伴随的休克、糖尿病、癌转移等方面具有用途。
• NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1604981A1

  公开（公告）日：2005-12-14

  A compound represented by the following general formula (I), its salt, solvates thereof or prodrugs thereof: (wherein each symbol is as defined in the description.) The compounds represented by the general formula (I) are useful in preventing and/or treating various inflammatory diseases (asthma, nephritis, nephropathy, hepatitis, arthritis, rheumatoid arthritis, rhinitis, conjunctivitis, ulcerative colitis, etc.), immunological diseases (autoimmune diseases, rejection in organ transplantation, immunosuppression, psoriasis, multiple sclerosis, etc.), infection with human immunodeficiency virus (acquired immunodeficiency syndrome, etc.), allergic diseases (atopic dermatitis, urticaria, allergic bronchoplumonary aspergillosis, allergic eosinophilic gastroenteritis, etc.), ischemic reperfusion injury, acute respiratory distress syndrome, shock accompanying bacterial infection, diabetes, cancer metastasis and so on.

  由以下通式（I）代表的化合物、其盐、溶液或原药： (通式（I）代表的化合物可用于预防和/或治疗各种炎症性疾病（哮喘、肾炎、肾病、肝炎、关节炎、类风湿性关节炎、鼻炎、结膜炎、溃疡性结肠炎等）、免疫性疾病（自身免疫性疾病、器官移植中的排异反应、免疫抑制、银屑病、多发性硬化症等）、人类免疫缺陷病毒感染（获得性免疫缺陷综合征等）、过敏性疾病（哮喘、肾炎、肾病、肝炎、风湿性关节炎、鼻炎、结膜炎、溃疡性结肠炎等）。过敏性疾病（特应性皮炎、荨麻疹、过敏性支气管曲霉病、过敏性嗜酸性粒细胞性胃肠炎等）、缺血再灌注损伤、急性呼吸窘迫综合征、细菌感染引起的休克、糖尿病、癌症转移等。
• EP1623721A1
  申请人：——

  公开号：EP1623721A1

  公开（公告）日：2006-02-08
• Function Inhibitor of Effector Cell
  申请人：Shibayama Shiro

  公开号：US20070270429A1

  公开（公告）日：2007-11-22

  The present invention relates to a function inhibitor of an effector cell comprising a CCR5 antagonist. Since the function inhibitor of an effector cell comprising a CCR5 antagonist inhibits the function of effector cells which play an important role in formation of diseases and the like, it is effective for the prevention and/or treatment of, for example, a transplant rejection (e.g., rejection of a solid organ graft, rejection of islet cell transplantation in diabetes mellitus, graft-versus-host disease (GVHD), etc.), an autoimmune disease (e.g., arthritis, rheumatoid arthritis, multiple sclerosis, ulcerative colitis, etc.), an allergic disease (e.g., asthma, etc.), an ischemic disease (e.g., ischemia-reperfusion injury, etc.), cancer or a metastatic disease or the like.
• US7910741B2
  申请人：——

  公开号：US7910741B2

  公开（公告）日：2011-03-22